LCDActive
BDX-XL2
L37031
Effective: April 28, 2022
Updated: December 31, 2025
Policy Summary
BDX-XL2 is covered for patients aged 40 or older with a solitary lung nodule 8–30 mm in diameter and a Mayo Clinic Model–calculated pre-test cancer risk of 50% or less, to identify nodules likely benign and enable CT surveillance instead of invasive procedures. Coverage is limited to use in lung nodule management and requires documentation of nodule size, patient age, and the Mayo Clinic pre-test risk calculation.
Coverage Criteria Preview
Key requirements from the full policy
"BDX-XL2 is covered for management of a lung nodule 8–30 mm in diameter in patients aged 40 years or older with a pre-test cancer risk, as assessed by the Mayo Clinic Model for Solitary Pulmonary No..."
Sign up to see full coverage criteria, indications, and limitations.